HAYWARD, Calif., Sept. 12 /PRNewswire/ -- Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced today that Astellas Pharma Inc. has begun high-throughput screening against another target from Metabolex's proprietary database of human genes associated with insulin resistance and obesity in order to identify potential drug candidates.
